Stocks Hitting 52-Week Highs

Medivation (NASDAQ: MDVN ) shares touched a new 52-week high of $86.54 after the company and Astellas reported final results from the Phase 3 PREVAIL trial of Enzalutamide. Credit Suisse lifted the price target on Medivation from $80.00 to $95.00. Teva Pharmaceutical Industries (NYSE: TEVA ) shares reached a